Definium moves toward FDA submission for LSD drug in anxiety after 'another clear win'

Definium Therapeutics reported positive Phase 3 trial results for its LSD-based drug DT120 in generalized anxiety disorder, moving closer to FDA submission for regulatory approval.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.